Prevention and management of enterococcal infection: cost implications.

Abstract

Enterococcal infections are becoming increasingly prevalent, in part because of the widespread use of cephalosporins and a greater number of immunosuppressed patients. Most infections where enterococci are isolated are pelvic or intraabdominal. The actual pathogenic role of the enterococcus remains controversial, since many types of organisms are usually cultured as well. Although specific therapy directed at the enterococcus may not always be necessary, reasonable indications for specific therapy include the presence of shock, immunosuppression, or persistent or recurrent infection. Enterococcal bacteremia is associated with a mortality rate in excess of 40 percent. This entity, as well as enterococcal endocarditis and meningitis, should be treated with bactericidal, combination antibiotic therapy, which includes a penicillin and an aminoglycoside. Mixed infections probably can be treated with a penicillin alone. Penicillin-allergic patients should be treated with vancomycin. The costs of nosocomial infection or superinfection are very high; costs incurred as a result of enterococcal infection or superinfection may be prevented by avoiding prolonged prophylactic or broad-spectrum therapeutic regimens (such as cephalosporins) that lack antienterococcal activity. Extended-spectrum penicillins may be effective prophylactic regimens for intraabdominal or pelvic procedures and should serve as adequate therapy for mixed infections in these sites.